JCRS Highlights

THOMAS KOHNEN European Editor of JCRS

NEW GLISTENING-FREE HYDROPHOBIC IOL PERFORMS WELL

The new CT LUCIA 611P IOL monofocal single-piece hydrophobic acrylic intraocular lens (IOL) achieved excellent refractive predictability, stability, and visual performance in a multicentre US clinical trial. In the study, 339 eyes of 339 patients underwent implantation of the new IOL. Among 310 eyes with 12 months follow-up, 85.8% (266/310) were within 0.5 D of emmetropia, and implanted (300/310) were within 1.0 D at their last visit. Manifest refraction spherical equivalent remained stable throughout follow-up with a mean value of 0.03 D at 12 months. Furthermore, the mean 12-month uncorrected distance visual acuity was 0.09 logMAR and the mean corrected distance visual acuity was 0.02 logMAR. Regarding posterior capsule opacification, only 3.5% (11/310) underwent Nd:YAG capsulotomy within the first year. Moreover, none of the IOLs developed glistenings. In adverse events, there were two cases of IOL tilt, neither of which caused visual symptoms, and two cases of IOL decentration, one of which required IOL removal. S C Schallhorn et al, “Outcomes of a multicenter US clinical trial of a new monofocal single-piece hydrophobic acrylic IOL”, 48(10): 1126–1133.

SHAPE-CHANGING PRESBYOPIC IOL SAFE AND EFFECTIVE

A new shape-changing presbyopic IOL appears to provide clear functional vision performance across a range of distances with an acceptable safety profile, according to the results of a prospective multicentre noncomparative clinical trial. The new lens, called the Juvene IOL (JIOL, LensGen, Inc.), is composed of a circumferential blue haptic and carries a clear central optic and a fluid lens with a flexible anterior surface filled with proprietary silicone oil. The lens is designed to transfer natural capsular bag forces to the haptic, causing compression of the fluid lens. Among 58 eyes that completed the 12-month visit, the mean monocular logMAR-corrected distance visual acuity, distance-corrected intermediate visual acuity, and distance-corrected near visual acuity were 0.01, 0.08, and 0.24, respectively. The most frequent adverse events were prolonged inflammation in six eyes and cystoid macular oedema in four eyes. All resolved without sequelae by the 12-month visit. S Garg, “Twelvemonth clinical outcomes after implantation of a new, modular, anterior shape-changing fluid optic intraocular lens”, 48(10): 1134–1140.

POOR EVIDENCE FOR OCULAR INJECTIONS FOR POST-CATARACT OEDEMA

Ocular injections to treat post-cataract macular oedema have shown promise in many published studies—but a new systematic review shows all those studies suffer from moderate to high degrees of bias. The review authors analysed 18 studies involving intravitreal steroid injections, intravitreal vascular endothelial growth factor inhibitor injections, intravitreal tumour necrosis factor-alpha inhibitor injections, posterior sub-Tenon steroid injections, or intravitreal steroid implants. They found that using the Cochrane Collaboration risk of bias tools, 15 studies (83%) had high risk for bias, and the remaining three a moderate risk for bias. The most common sources of bias were lack of reproducibility of methods, unmasked assessments, lack of statistical testing, selective reporting of results, and missing outcomes data. G Ahmadyar, “Ocular injectable treatment options for postcataract macular edema: systematic review”, 48(10): 1197–1202.

OS 4TM THE NEXT GENERATION

Not available for sales in the US *Oertli data on file The new OS 4 marks the beginning of the next generation of retina, glaucoma and cataract surgery. The all-in-one platform has received numerous exciting features that provide even more comfort, precision and safety.

NEW FEATURE

Laser integration: More safety, fully automated user protection filter Light: 45% more power*, maximum visibility

Pedal: Multifunctional with over 100 setting options

Phaco: Speedier readiness, greater controllability

User comfort: Even more user- friendly and communicative

Make the difference – with the new OS 4: www.oertli-instruments.com

EYE SURGERY. SWISS MADE.